Researchers reported that a circular RNA gene therapy leveraging endogenous ADAR enabled safe and durable exon skipping repairs in human and nonhuman primate models of Duchenne muscular dystrophy. The work centers on endogenous RNA-editing machinery (ADAR) to modify DMD transcripts for downstream functional restoration. For the DMD field, exon skipping remains a major therapeutic route, but durability and tolerability are key barriers for many approaches. The inclusion of both humans and nonhuman primates strengthens translational relevance and supports continued preclinical-to-clinical momentum. Industry focus now turns to whether the therapy can deliver sustained functional benefits, avoid unwanted editing, and scale manufacturability for repeated or long-term dosing strategies.